Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest cyclophosphamide Stories

Non-Toxic Therapy For Lupus Successfully Tested On Patients
2013-11-12 09:38:48

Rebekah Eliason for redOrbit.com – Your Universe Online Scientists from Northwestern Medicine have brought new hope to patients with lupus. A new nontoxic therapy that suppresses lupus in blood samples was designed and successfully tested on patients with the autoimmune disease. There is hope this treatment will replace the use of toxic drugs that carry nasty side effects with a vaccine like therapy. This new treatment could keep lupus in remission in the body. Lupus is a...

2013-08-01 14:43:22

In an article published today in the New England Journal of Medicine, Immune Tolerance Network (ITN) researchers demonstrated that a single course of rituximab therapy (anti-CD20; Rituxan, Genentech, Inc.) is as effective as the current standard of care regimen of drugs for remission induction and maintenance in patients with ANCA-associated Vasculitis (AAV). AAV is an autoimmune disease marked by the presence of antibodies that attack neutrophils and cause inflammation of the blood vessels,...

2013-06-03 08:28:12

Activity with VAL-083 Observed in Recurrent Malignant Glioma and Progressive Secondary Brain Tumors VANCOUVER, British Columbia and MENLO PARK, Calif., June 3, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced that the company presented a poster entitled "Phase I/II Study of VAL-083 (dianhydrogalactitol) in Patients with Recurrent Malignant Glioma or Progressive Secondary Brain Tumor" at the American Society of Clinical Oncology (ASCO) Annual...

Drug Substitions Due To Shortages Could Prove Harmful For Cancer Patients
2012-12-27 13:20:56

Lee Rannals for redOrbit.com — Your Universe Online According to research led by St. Jude Children's Research Hospital, there is a connection between higher rates of relapse in pediatric cancer patients and drug shortages. A national drug shortage was linked to a higher rate of relapse among children, teenagers and young adults with Hodgkin's lymphoma, according to the national study. Survival from the condition went from 88 to 75 percent in two years after the drug...

2012-12-26 16:21:07

National study connects higher rates of relapse in pediatric cancer patients to drug shortage, offering first example of patients hurt by shortages and renewing calls to protect patient access to lifesaving treatments MEMPHIS, Tenn., Dec. 26, 2012 /PRNewswire-USNewswire/ -- A national drug shortage has been linked to a higher rate of relapse among children, teenagers and young adults with Hodgkin lymphoma enrolled in a national clinical trial, according to research led by St. Jude...

2012-08-16 02:24:20

CALGARY, Aug. 16, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that it has completed patient enrollment in its U.K. Phase I clinical trial using intravenously-administered REOLYSIN in combination with cyclophosphamide in patients with advanced malignancies (REO 012). "We are pleased to complete enrollment of this technical study examining cyclophosphamide's potential to modulate the immune system's response to REOLYSIN," said Dr....

2012-05-15 12:44:25

Researchers found that administering a common chemotherapy drug before bone tumors took root actually fertilized the bone marrow, enabling cancer cells, once introduced, to seed and grow more easily. The findings provide valuable insight as to why some cancers metastasize to bone, and could eventually result in new metastasis-prevention drugs, said Laurie McCauley, professor in the Department of Periodontics and Oral Medicine at the University of Michigan School of Dentistry and principal...

2010-12-09 08:00:00

BRIDGEWATER, N.J., Dec. 9, 2010 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the final survival analysis (10-year follow-up) of the BCIRG001 study that included a Taxotere® (docetaxel) Injection Concentrate chemotherapy treatment regimen in the adjuvant breast cancer setting, as well as data from iniparib (BSI-201) pre-clinical and clinical breast cancer studies will be featured during the 33rd Annual San Antonio Breast...

2010-11-18 06:30:00

CALGARY, Nov. 18 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Children's Oncology Group (COG) intends to conduct a Phase I trial of REOLYSIN((R)) in combination with cyclophosphamide in pediatric patients with relapsed or refractory solid tumors. The study will be conducted in collaboration with the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which...

2010-11-05 15:46:20

Patients have better treatment options than ever before Today, individuals with lupus nephritis benefit from better treatments than a decade ago, according to a review appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The article suggests that patients with the disease can now live full lives without suffering from many treatment-related side effects that plagued them in the past. In the future, patients will likely experience additional benefits from...